Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stage IA Cervical Cancer Treatment
Equivalent treatment options:Total hysterectomy. If the depth of invasion is less than 3 mm proven by cone biopsy with clear margins  and no vascular or lymphatic channel invasion is noted, the frequency of lymph node involvement is sufficiently low that lymph node dissection is not required. Oophorectomy is optional and should be deferred for younger women. Conization. If the depth of invasion is less than 3 mm, no vascular or lymphatic channel invasion is noted, and the margins of the cone are negative, conization alone may be appropriate in patients wishing to preserve fertility.Modified radical hysterectomy. For patients with tumor invasion between 3 mm and 5 mm, radical hysterectomy with pelvic node dissection has been recommended because of a reported risk of lymph node metastasis of as much as 10%. However, a study suggests that the rate of lymph-node involvement in this group of patients may be much lower and questions whether conservative therapy might be
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stage IVB Cervical Cancer Treatment
The size of the primary tumor is an important prognostic factor and should be carefully evaluated in choosing optimal therapy. Survival and local control are better with unilateral rather than bilateral parametrial involvement. Patients who are surgically staged as part of a clinical trial and are found to have small volume para-aortic nodal disease and controllable pelvic disease may be cured with pelvic and para-aortic radiation therapy. If postoperative external-beam radiation therapy (EBRT) is planned following surgery, extraperitoneal lymph node sampling is associated with fewer radiation-induced complications than a transperitoneal approach. The resection of macroscopically involved pelvic nodes may improve rates of local control with postoperative radiation therapy. Treatment of patients with unresected periaortic nodes with extended-field radiation therapy leads to long-term disease control in those patients with low volume (<2 cm) nodal disease below L3.
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Recurrent Uterine Sarcoma
There is currently no standard therapy for patients with recurrent disease. These patients should be entered into an ongoing clinical trial. Patients who present with uterine sarcoma have been treated on a series of phase II studies by the Gynecologic Oncology Group, including the GOG-87B trial, for example. These chemotherapy studies have documented some antitumor activity for cisplatin, doxorubicin, and ifosfamide. These studies have also documented differences in response leading to separate trials for patients with carcinosarcomas and leiomyosarcomas. As an example, in patients previously untreated with chemotherapy, ifosfamide had a 32.2% response rate in patients with carcinosarcomas, a 33% response rate in patients with endometrial stromal cell sarcomas, and a 17.2% partial response rate in patients with leiomyosarcomas. Doxorubicin in combination with dacarbazine or cyclophosphamide is no more active than doxorubicin alone for recurrent disease.[4,5] Cisplatin has
Cervical Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Recurrent Endometrial Cancer
For patients with localized recurrences (pelvis and periaortic lymph nodes) or distant metastases in selected sites, radiation therapy may be an effective palliative therapy. In rare instances, pelvic radiation therapy may be curative in pure vaginal recurrence when no prior radiation therapy has been used. Patients positive for estrogen and progesterone receptors respond best to progestin therapy. Among 115 patients with advanced endometrial cancer who were treated with progestins, 75% (42 of 56 patients) of those with detectable progesterone receptors in their tumors before treatment responded, compared with only 7% without detectable progesterone receptors (4 of 59 patients). A receptor-poor status may predict not only poor response to progestins but also a better response to cytotoxic chemotherapy. Evidence suggests that tamoxifen (20 mg twice a day) will give a response rate of 20% in those who do not respond to standard progesterone therapy.Several randomized trials
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stage I Uterine Sarcoma
Standard treatment options: Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and periaortic selective lymphadenectomy).Surgery plus pelvic radiation therapy.Surgery plus adjuvant chemotherapy.Surgery plus adjuvant radiation therapy as seen in the EORTC-55874 trial, for example.In a nonrandomized, Gynecologic Oncology Group study in patients with stage I and II carcinosarcomas, those who had pelvic radiation therapy had a significant reduction of recurrences within the radiation treatment field but no alteration in survival. A large nonrandomized study demonstrated improved survival and a lower local failure rate in patients with mixed mullerian tumors following postoperative external and intracavitary radiation therapy. One nonrandomized study that predominantly included patients with carcinosarcomas appeared to show benefit for adjuvant therapy with cisplatin and doxorubicin.Current Clinical TrialsCheck for U.S. clinical trials from NCI's
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stage Information for Endometrial Cancer
Definitions: FIGOThe Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) and the American Joint Committee on Cancer (AJCC) have designated staging to define endometrial cancer; the FIGO system is most commonly used.[1,2]Carcinosarcomas should be staged as carcinoma. FIGO stages are further subdivided by the histologic grade of the tumor, for example, stage IC G2.Table 1. Carcinoma of the EndometriumaStagea Adapted from FIGO Committee on Gynecologic Oncology.b Either G1, G2, or G3 (G = grade).c Endocervical glandular involvement only should be considered as stage I and no longer as stage II.d Positive cytology has to be reported separately without changing the stage.IbTumor confined to the corpus uteri.IAbNo or less than half myometrial invasion.IBbInvasion equal to or more than half of the myometrium.IIbTumor invades cervical stroma but does not extend beyond the uterus.cIIIbLocal and/or regional spread of the tumor.IIIAbTumor invades the serosa of the corpus
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - General Information About Cervical Cancer
WebMD explains the types of cervical cancer and the prognosis when you're diagnosed in different stages.
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (04 / 12 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. This summary was renamed from Gestational Trophoblastic Tumors and Neoplasia Treatment.General Information About Gestational Trophoblastic Disease This section was renamed from General Information About Gestational Trophoblastic Tumors and Neoplasia.Revised text to state that gestational trophoblastic disease (GTD) is a broad term encompassing both benign and malignant growths arising from products of conception in the uterus.Revised text to state that GTD may be classified as: hydatidiform mole (HM) including complete HM and partial HM; gestational trophoblastic neoplasia including Invasive mole, choriocarcinoma, and placental-site trophoblastic tumor; and, epithelioid trophoblastic tumor.Cellular Classification of Gestational Trophoblastic DiseaseThis section was renamed from Cellular
Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Treatment Options for Recurrent Cervical Cancer
Treatment of recurrent cervical cancer may include the following:Pelvic exenteration followed by radiation therapy combined with chemotherapy.Chemotherapy as palliative therapy to relieve symptoms caused by the cancer and improve quality of life.Clinical trials of new anticancer drugs or drug combinations.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent cervical cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.